Get notified of page updates

Our Featured Research Page lists cancer prevention, treatment and quality of life studies enrolling people with or at high risk for hereditary cancers. You can do a quick search to filter our featured studies by cancer type, study type or key word, or a more in-depth search through

How to Use Our Search and Enroll Tool

Search Results: Treatment + Prostate Cancer + Hormone Sensitive (1 results)

Printer Friendly Page 1 through 1 of 1
Treatment for Metastatic Castration-Sensitive Prostate Cancer and Inherited or Tumor Mutations in DNA Damage Repair Genes (Amplitude)

Treatment for metastatic castration-sensitive prostate cancer and a tumor or inherited mutation in BRCA1, BRCA2, ATM, BRIP1, CHEK2, PALB2 or related gene

Treatment for Metastatic Castration-Sensitive Prostate Cancer and Inherited or Tumor Mutations in DNA Damage Repair Genes (Amplitude)

The goal of AMPLITUDE is to see if adding the PARP inhibitor niraparib to standard of care hormone therapy (Abiraterone Acetate, prednisone and androgen deprivation therapy (ADT) is safe and more effective than standard of care alone. The study is enrolling people who have metastatic castration-sensitive prostate cancer and have an inherited or tumor mutation in one of the following genes involved in DNA damage repair: BRCA2, BRCA1, BRIP1, CHEK2, FANCA, PALB2, RAD51B and RAD54L.

More info
Additional Results on Treatment + Prostate Cancer + Hormone Sensitive + adt
60 results
Clinical Trial Official Title
NCT04748042 Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)
NCT04298983 Abemaciclib in Combination With Androgen Deprivation Therapy for Locally Advanced Prostate Cancer
NCT05628363 Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer
NCT05477823 Imaging and Genomic Biomarkers to Predict Response in Prostate Cancer
NCT05361798 T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine M9241 in Localized High- and Intermediate-Risk Prostate Cancer Treated With Androgen Deprivation Therapy
NCT03543189 Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy
NCT04465500 EBRT and HDR Brachytherapy for Unfavorable-intermediate, High, and Very High-risk Prostate Cancer
NCT04947254 Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
NCT05100472 A Study of Shorter Course Hormone Therapy and Radiation for High-risk Prostate Cancer
NCT05169970 A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer
NCT05676463 MRI Guided Radiation Therapy for the Treatment of High Risk Prostate Cancer
NCT03361735 Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
NCT04349501 Biomarker Monitoring of Prostate Cancer Patients With RSI MRI (ProsRSI)
NCT01985828 CyberKnife® as Monotherapy or Boost SBRT for Intermediate or High Risk Localized Prostate Cancer
NCT04402151 Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer
NCT04943536 Bicalutamide Implants (Biolen) With Radiation Therapy in Patients With Localized Prostate Cancer
NCT03553602 BEACON: HDR Brachytherapy, EBRT and STAD for the Treatment of Local and Pelvic Recurrence of Prostate Cancer After Radiation Therapy
NCT05155046 18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy
NCT05568550 Pembro With Radiation With or Without Olaparib
NCT05320406 RElugolix VErsus LeUprolide Cardiac Trial
NCT05915442 Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer
NCT03624660 Dose-Escalated Proton Radiation Therapy for High-Risk Prostate Cancer
NCT04025372 INTREPId (INTermediate Risk Erection PreservatIon Trial)
NCT04019964 Nivolumab in Biochemically Recurrent dMMR Prostate Cancer
NCT03456843 Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer
NCT05053152 Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer
NCT04734730 Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
NCT04725903 Proton Radiation Therapy for the Treatment of Patients With High Risk Prostate Cancer
NCT04705038 Effect of Education on Treatment Decision Making for Patients With Prostate Cancer on Chronic Hormone Treatments
NCT04633252 M9241 in Combination With Docetaxel in Adults With Metastatic Castration Sensitive and Castration Resistant Prostate Cancer
NCT03413995 Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations
NCT05617885 Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer
NCT05133440 A Study of Stereotactic Body Radiation Therapy and Radium (Ra-223) Dichloride in Prostate Cancer That Has Spread to the Bones
NCT05050084 Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score
NCT04787744 Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for OligoRecurrenT Prostate Cancer
NCT04704505 Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT04126070 Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors
NCT04513717 Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
NCT04116775 Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer.
NCT02040610 Hypofractionated Image Guided Proton Therapy for Low andIntermediate Risk Prostate Cancer
NCT03436654 Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma
NCT04363164 Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression
NCT05496959 177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study
NCT05169684 A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer
NCT03796767 Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer
NCT04493853 Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency
NCT04677855 Study of PCUR-101 in Combination With ADT in Patients With mCRPC
NCT03934840 CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone
NCT04423211 Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
NCT04666129 Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer
NCT05617040 Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer
NCT05348577 Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT04175431 Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study
NCT05605964 Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate
NCT04253483 Comparison of High-Dose Rate Brachytherapy and Stereotactic Ablative Radiotherapy as Monotherapy for the Treatment of Localized Prostate Cancer
NCT04288687 A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects
NCT04421222 Oral EPI-7386 in Patients With Castration-Resistant Prostate Cancer
NCT04188535 Serial MRI Scans During Radiation Therapy
NCT03637543 Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer
NCT05498272 Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With BRCA1/2 Gene Alterations

Research Search Tool Sponsored By:

Merck & Co., Inc.
Mike & Patti Hennessy Foundation